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ABSTRACT
Background
The aim of this study was to determine the impact of a gain of the MALT1 gene on gene expres-
sion and clinical parameters in diffuse large B-cell lymphoma.
Design and Methods
We analyzed 116 cases of diffuse large B-cell lymphoma by fluorescence in situ hybridization,
array-based comparative genomic hybridization, and transcriptional profiling.
Results
A gain of 18q21 including MALT1 was detected in 44 cases (38%) and was accompanied by a
gain of BCL2 in 43 cases. All cases with a 18q21/MALT1 gain showed BCL2 protein expression,
whereas 79% in the group without a 18q21/MALT1 gain did so (p<0.001). Cases with 18q21/
MALT1 gain more frequently showed an activated B-cell-like (ABC) gene expression signature
(65%) than a germinal center B-cell-like (GCB) one (23%) (p<0.001). Ninety-eight genes includ-
ing MALT1, BCL2, and some selected nuclear factor-κB target genes were differentially expressed
between the two genetic groups of diffuse large B-cell lymphoma. By global testing of each chro-
mosome, we identified 33 genes, all located on chromosome 18q, which were differentially
expressed between the two genetic groups independently of the ABC/GCB status. In multivariate
analysis, the 18q21/MALT1 status represented an independent negative prognostic factor for
overall survival (p=0.03).
Conclusions
In diffuse large B-cell lymphoma, gain of 18q21 including MALT1 is significantly associated with
differential expression of genes located on 18q, the ABC gene expression subtype, increased
BCL2 gene and protein expression and might indicate an unfavorable prognosis.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
frequent lymphoma in adults, accounting for 30% to
40% of lymphoid neoplasms.1 The diversity in clinical
presentation and outcome, as well as the pathological
and biological heterogeneity suggest that DLBCL com-
prises several disease entities that may require different
therapeutic approaches.2-4
Recent gene expression profiling studies have identi-
fied several prognostically different subgroups of
DLBCL with gene expression patterns indicative of the
different stages of B-cell differentiation, termed germi-
nal center B-cell-like (GCB), activated B-cell-like (ABC),
and primary mediastinal (PM) DLBCL,5-7 as well as acti-
vation of distinct biological pathways, especially oxida-
tive phosphorylation, B-cell receptor/proliferation, and
host response.8,9 In addition, we recently defined the
gene expression signature of Burkitt’s lymphoma and
showed that a small proportion of DLBCL also bears
this signature.10 Patients with a “molecular Burkitt’s
lymphoma signature” were younger, in a less advanced
clinical stage, and a had better clinical outcome com-
pared to patients without this signature.10 The 5-year
survival rates of patients with GCB-DLBCL, ABC-
DLBCL, and PM-DLBCL are 59%, 30%, and 64%,
respectively.5-7 GCB-DLBCL is characterized by recur-
rent REL amplification, BCL2 translocations,6,11 and
ongoing somatic hypermutation of the immunoglobu-
lin genes.12 In contrast, ABC-DLBCL has constitutively
activated transcription factor nuclear factor (NF)-κB,
which plays a critical role in the pathogenesis of this
lymphoma,13-15 and BCL2 protein overexpression in the
absence of the t(14;18).16 The mechanisms underlying
BCL2 overexpression in t(14;18)-negative DLBCL are
largely unknown. Since BCL2 is a target gene for NF-
κB17 and NF-κB is constitutively expressed in ABC-
DLBCL, BCL2 upregulation may be mediated through
NF-κB. Another possible mechanism resulting in BCL2
protein overexpression is a gain of BCL2, as recently
shown by Iqbal et al.16 
In this scenario, the role of the MALT1 gene, which
lies close to BCL2 on chromosomal band 18q21 and has
an important impact on NF-κB activation, was not




This study is part of the German network project
Molecular Mechanisms of Malignant Lymphomas, for
which ethic approval was obtained. Mature aggressive
B-cell lymphomas with more than 70% of tumor cells
were analyzed by a comprehensive approach including
gene expression profiling, array-based comparative
genomic hybridization (array-CGH), and interphase
fluorescence in situ hybridization (FISH).10 The diag-
noses were established by seven expert hematopathol-
ogists, who evaluated morphology and immunohisto-
chemistry in a centralized panel review as previously
described.10 The intensity of BCL2 expression by the
tumor cells was determined in relation to that of BCL2-
positive reactive T-cells. Only lymphomas with an
intensity of BCL2 expression similar to or stronger than
that of reactive T cells and with more than 25% of
BCL2-positive tumor cells were scored as BCL2-posi-
tive.
We included all cases analyzed in the above men-
tioned network project until December 2005 which ful-
filled the following criteria: (i) a histopathologic diag-
nosis of DLBCL according to the WHO classification,
(ii) lack of a molecular Burkitt’s lymphoma signature,
(iii) samples not from patients with relapse, human
immunodeficiency virus-infection, or PM-DLBCL, (iv)
interphase FISH evaluable for imbalances of the BCL2
and MALT1 loci. 
From 142 DLBCL cases with available interphase
FISH results, 10 cases were excluded because they car-
ried a molecular Burkitt’s lymphoma signature and 16
further cases were excluded because relapse of the lym-
phoma, a human immunodeficiency virus-infection, or
a PM-DLBCL was diagnosed. None of the ten DLBCL
with a molecular Burkitt’s lymphoma signature
showed a gain of MALT1 or BCL2. Thus, a total of 116
cases entered the study (Table 1). Clinical and survival
data were available for 81 of these patients (Table 2).
The median follow-up time of these patients was 5
years (range, 0 to 209 months). 
Fluorescence in situ hybridization
Interphase FISH was performed on 5 µm thick frozen
tissue sections according to standard methods. Two
hundred interphase nuclei were analyzed in each case
by at least two independent investigators. Gene ampli-
fication was defined by the presence of a cloud-like sig-
nal accumulation or more than five individual signals in
the interphase cells. A gain of the respective gene was
defined by the presence of three to five hybridization
signals per interphase nucleus occurring in more than
5% of nuclei. In cases with a gain of MALT1 or BCL2,
as shown by interphase FISH and a balanced array-
CGH status for these genes, further FISH analyses were
evaluated for imbalances of the BCL6, MYC, and IGH
loci to differentiate polysomies of 18q21 from poly-
ploid karyotypes without a real 18q21 gain.  The
MALT1 and the BCL2 loci were analyzed using dual
color FISH with probe LSI® MALT1 Dual Color, Break
Apart Rearrangement Probe and probe LSI® IGH/BCL2
Dual Color, Dual Fusion Translocation Probe, respec-
tively (both from Abbott Vysis, Downers Grove, IL,
USA).  In addition, as described by Hummel et al.,10
breakpoints within the MYC, BCL6, and IGH genes
were analyzed with the LSI® MYC, LSI® BCL6, and LSI®
IGH break apart assays (all from Abbott Vysis) and
MYC partners with the LSI® IGH/MYC (Abbott Vysis)
and home-brewed IGK-MYC and IGL-MYC double-
color, double-fusion assays.10  
Array-CGH
Array-CGH was performed as previously
described.10,18,19 A 2.8k array CGH chip containing 2799
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fragments was applied. The previously published
GoldenPath clone set20 served as the backbone for the
set up of the chip. In total, 1500 DNA clones at inter-
vals of approximately 2 Mb were selected. This compi-
lation was enriched by 600 DNA fragments, which rep-
resent critical regions in B-cell neoplasms as well as 699
additional DNA fragments containing proto-oncogenes
or tumor suppressor genes. DNA preparations of all
BAC and PAC clones and subsequent degenerate
oligonucleotide primed (DOP) polymerase chain reac-
tion (PCR)-mediated DNA amplification were per-
formed as described by Fiegler et al.21 The PCR products
were spotted onto Corning CMT-Gaps II glass slides
using an Omnigrid microarrayer (Gene Machines, San
Carlos, CA, USA). DNA labeling, hybridization and
data acquisition was done as recently described.10,18,19
The ratios of two hybridizations with reversed dye
labeling were averaged and normalized. The diagnostic
cut-off level for each individual experiment was deter-
mined by calculating the mean and subsequently using
plus/minus three standard deviations of all clones from
chromosomes 1 to 22.
Affymetrix GeneChip hybridization and statistical
analysis of the microarray data
Affymetrix hybridization was carried out with the
U133A GeneChips according to the manufacturer's rec-
ommendations, as previously described.10 Probe inten-
sities were normalized using a variance stabilization
method.22 Gene expression levels were estimated by
fitting an additive model23 employing a median polish
routine. The significance of differential gene expression
was analyzed with a two-step procedure, a global step
and a gene-by-gene step. Global tests for differential
gene expression were performed for predefined sets of
genes using the ANCOVA test of Mansmann and
Meister.24 This test allows several factors to be included
in a linear model and analyzed separately for differen-
tial gene expression. The resulting empirical permuta-
tion p values were adjusted for multiplicity using
Bonferroni’s correction since multiple chromosomes
were tested at the same time. We included the
ABC/GCB type of the lymphomas in the model when
testing for the impact of a MALT1 gain on gene expres-
sion. In order to determine lists of differentially
expressed genes we performed a gene-by-gene analysis
using the method of Smyth et al.25 GCB and ABC sam-
ple labels were computed according to Wright et al.26
The data presented are available from the Gene
Expression Omnibus (GEO) of the National Center for
Biotechnology Information (www.ncbi.nlm.nih.gov/geo/)
through GEO accession number GSE4475 (the patients’
identification numbers (MPI-number) are shown in
Online Supplementary Figure S1).
Statistical analysis of genetic, histopathological, and
clinical data
Mann-Whitney U, χ2, Fisher’s exact, and log-rank
tests were applied to test for differences between
groups. Survival was calculated from the day of diag-
nosis until death or the end of follow-up. Time-to-
treatment-failure (TTTF) was calculated from the day
of diagnosis until progression, relapse, start of salvage
therapy, end of therapy without complete remission or
death. A Cox proportional hazard model was
employed to analyze prognostic factors. Since not all
parameters of the International Prognostic Index were
available for all cases, age at diagnosis and Ann Arbor
stage were used to adjust for known prognostic fac-
tors.27
Results
Interphase FISH and array CGH: the minimal
overrepresented region on chromosome 18 lies
in 18q21 and includes MALT1
According to array-CGH, the minimal overrepre-
sented region on chromosome 18 was delineated to a
3.9 Mb region in 18q21.2 to 18q21.31 (clones RP11-
7L24 to RP11-350K6) and encompassed 15 annotated
genes including MALT1, but not BCL2. The telomeric
Table 1. Morphological, immunohistochemical, and genetic char-
acteristics of 116 DLBCL with and without a gain of 18q21 includ-
ing MALT1.
Normal Gain of 18q21/MALT1 p*
CD10 ICH
negative 44 (61%) 34 (77%) 0.056
positive 26 (36%) 8 (18%)
n.a. 2 (3%) 2 (5%)
BCL2 IHC
negative 14 (19%) 0 (0%) <0.001
pos. 57 (79%) 44 (100%)
n.a. 1 (1%) 0 (0%)
BCL6 IHC
negative 12 (17%) 14 (32%) 0.104
positive 53 (74%) 27 (61%)
n.a. 7 (10%) 3 (7%)
Ki67-index
<95 66 (92%) 34 (77%) 0.016
≥95 4 (6%) 10 (23%)
n.a. 2 (3%) 0 (0%)
MYC-partner
IG-MYC 14 (19%) 3 (7%) 0.153
non-IG-MYC 5 (7%) 5 (11%)
MYC negative 53 (74%) 35 (80%)
n.a. 0 (0%) 1 (2%)
IGH-BCL2-fusion
negative 57 (79%) 41 (93%) 0.063
positive 15 (21%) 3 (7%)
BCL6-break
negative 49 (68%) 38 (86%) 0.069
positive 21 (29%) 6 (14%)
n.a. 2 (3%) 0 (0%)
Cell of origin
ABC 12 (17%) 29 (66%) <0.001
GCB 39 (54%) 10 (23%)
unclassified 21 (29%) 5 (11%)
*p values were calculated based on all cases that could be evaluated; n.a., not
available; IHC, immunohistochemistry.
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margin of this region was mainly defined by one case,
which showed an amplification of 18q21 including
MALT1 and a normal BCL2 status. The centromeric
margin was defined by another case showing an
amplification of 18q21 spanning exactly the minimal
overrepresented region between clones RP11-7L24 and
RP11-350K6 including MALT1. Interestingly, the
region telomeric to RP11-350K6 including BCL2 was
gained but not amplified.
From the 40 cases with a 18q gain, 30 cases (75%)
had a gain of 18q or part of it and ten (25%) had tri-
somy or polysomy of the whole chromosome.18
According to FISH, the MALT1 gene was gained in 44
of the 116 cases (38%). In all cases with a MALT1 gain
but one, a concomitant gain of BCL2 was detected by
interphase FISH and array-CGH. The latter case had
MALT1 amplification in 64% of the cells and a normal
BCL2 signal constellation (see array-CGH results). In the
remaining cases, the signal numbers for MALT1 and
BCL2 were similar, indicating a gain of the 18q21
region or part of it including both genes (further
referred to as gain of 18q21/MALT1). 
Among the 44 cases with a gain of MALT1, 28 (63%)
showed mainly three copies, six (14%) showed four
copies, six (14%) showed five copies, and four (9%)
had an amplification of MALT1. The percentage of cells
with a MALT1 or BCL2 gain ranged from 11% to 90%.
Array-CGH results corresponded well with the inter-
phase FISH results in 40 cases. In the remaining four
cases, interphase FISH revealed a trisomy of MALT1
and BCL2 together with two signals for the IGH, BCL6,
and MYC probes, but array-CGH showed a normal sig-
nal constellation for the BCL2 and MALT1 genes. In
these four cases, the percentage of cells bearing three
hybridization signals was 11%, 18%, 22%, and 40%.
The relatively low proportion of cells carrying the
abnormality was possibly the reason why these gains
were not detected by array-CGH.18 These cases were
assigned as gain of 18q21. All cases without gains of
MALT1 and/or BCL2 by FISH had normal array-CGH
results for these regions. 
The group without a 18q21/MALT1 gain showed a
higher frequency of IGH-BCL2 fusions (p=0.06) and
breaks in the BCL6 locus (p=0.07), but  the difference in
frequency was not statistically significant (Table 1).
Three cases with 18q21/ MALT1 gains showed a IGH-
BCL2 fusion. In one case, array-CGH revealed a tetra-
somy 18. In the other two cases, the gains involved the
18q12.1-18q21.33 and 18q21.1-18q21.33 regions, and
the proximal border of the gain was telomeric of BCL2
in both cases. Breaks targeting MALT1 were not detect-
ed in any case. 
Gain of 18q21 including MALT1 correlates with an
ABC-DLBCL expression signature and differential
gene expression overlaps with that observed in
ABC- vs. GCB comparisons
Out of the 44 cases in the group with a 18q21/ MALT1
gain, 29 (66%) showed an ABC signature and 10 (23%)
had a GCB profile, whereas in the other 72 cases only
12 cases (17%) showed an ABC signature and 39 cases
(54%) had a GCB pattern (p<0.001) (Table 1).
In order to determine differential gene expression
between cases with and without a gain of
18q21/MALT1, we preceded in several steps. First, we
applied a global test for differential expression between
18q21/MALT1-positive and 18q21/MALT1-negative
patients, ignoring the ABC and GCB signatures. Global
ANCOVA returned an empirical permutation p value of
Table 2. Clinical characteristics of 81 DLBCL patients with and
without a gain of 18q21/MALT1.
All Normal Gain of p*
18q21/MALT1
Age
<60 25 (31%) 18 (38%) 7 (21%)
≥60 56 (69%) 30 (62%) 26 (79%) 0.146
Stage
I or II 31 (38%) 21 (44%) 10 (30%)
III or IV 41 (51%) 20 (42%) 21 (64%) 0.15
n.a. 9 (11%) 7 (15%) 2 (6%)
Gender
female 39 (48%) 23 (48%) 16 (48%)
male 42 (52%) 25 (52%) 17 (52%) 1
Nodal/extranodal
extranodal 11 (14%) 8 (17%) 3 (9%)
nodal 38 (47%) 21 (44%) 17 (52%)
nodal/extranodal 17 (21%) 8 (17%) 9 (27%) 0.482
n.a. 15 (19%) 11 (23%) 4 (12%)
B-symptoms
no 38 (47%) 24 (50%) 14 (42%)
yes 28 (35%) 15 (31%) 13 (39%) 0.459
n.a. 15 (19%) 9 (19%) 6 (18%)
Bone marrow involvement
no 50 (62%) 30 (62%) 20 (61%)
yes 10 (12%) 3 (6%) 7 (21%) 0.097
n.a. 21 (26%) 15 (31%) 6 (18%)
Bulk
no 25 (31%) 13 (27%) 12 (36%)
yes 13 (16%) 5 (10%) 8 (24%) 0.506
n.a. 43 (53%) 30 (62%) 13 (39%)
Chemotherapy
B-ALL like 2 (2%) 1 (2%) 1 (3%)
CHOP/COPBLAM- 57 (70%) 35 (73%) 22 (67%)
like
other 15 (19%) 8 (17%) 7 (21%) 0.79
n.a. 7 (9%) 4 (8%) 3 (9%)
Radiation therapy
no 52 (64%) 31 (65%) 21 (64%)
yes 18 (22%) 10 (21%) 8 (24%) 0.787
n.a. 11 (14%) 7 (15%) 4 (12%)
Rituxan
no 55 (68%) 31 (65%) 24 (73%)
yes 10 (12%) 6 (12%) 4 (12%) 1
n.a. 16 (20%) 11 (23%) 5 (15%)
Lactate dehydrogenase
low 17 (21%) 9 (19%) 8 (24%)
high 23 (28%) 12 (25%) 11 (33%) 1
n.a. 41 (51%) 27 (56%) 14 (42%)
Response to treatment
complete remission 31 (38%) 22 (46%) 9 (27%)
no change/ 10 (12%) 7 (15%) 3 (9%)
partial remission
progression 15 (19%) 4 (8%) 11 (33%) 0.14
n.a. 25 (31%) 15 (31%) 10 (30%)
*p values were calculated based on all cases that could be evaluated ; n.a., not
available.
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0.004. Hence, there is differential gene expression
between the two genetic subtypes of DLBCL. From a
gene-by-gene test we obtained a list of 135 Affymetrix
probe sets representing 98 differentially expressed
genes with an estimated false discovery rate of 0.05.
This list included MALT1 and BCL2 and some selected
NF-κB target genes. In the next step, we included the
GCB or ABC signature as a confounding factor in a full
linear model using global ANCOVA. We restricted this
part of the analysis to patients with an unambiguous
GCB or ABC signature and excluded cases with an
unclassified (type 3) signature. The global test for the
influence of a 18q21/MALT1 gain on gene expression
gave a negative result (p=0.41). It is not, therefore, pos-
sible to distinguish 18q21/MALT1- specific from ABC-
specific effects on gene expression.
Genomic gain of 18q21 including MALT1 is
significantly associated with RNA upregulation of
genes located on chromosome 18q including MALT1
Up to this point, we had only considered the global
gene expression profiles looking at all probe sets at the
same time. This represents a massive multiple testing
problem (>22,000 array features) compromising the
statistical power of the screening. In the following step
we, therefore, increased the power of the test by
including prior knowledge of the chromosomal loca-
tion of the genes. We applied a global test of gene
expression for each chromosome (excluding the X and
Y chromosomes, 22 tests) separately and adjusted the
22 p values for multiple testing. This test identifies
chromosomes with global changes in gene expression
between the two groups. Interestingly, only chromo-
some 18 displayed global changes in gene expression,
which were independent of the ABC/GCB status (padjust-
ed<0.03). To further elucidate this finding, we analyzed
the genes on chromosome 18 independently using a
gene-by-gene test and identified 47 probe sets repre-
senting 33 differentially expressed genes with an esti-
mated false discovery rate of 0.05. (Online Supplement-
ary Table S1 and Figure S1). These differentially
expressed genes included MALT1, SERPINB8,
NEDD4L, POLI, VPS4B, TXNL1, SMAD2, TCF4,
SMAD4 and PIK3C3, but not BCL2.
Upregulation of NF-κB target genes in the group with
a 18q21/MALT1 gain overlaps with ABC gene expres-
sion characteristics
Since MALT1 is known to activate the NF-κB path-
way and BCL2 is transcriptionally regulated by NF-κB,17
we assessed the differential expression of NF-κB target
genes in the groups with and without a 18q21/MALT1
gain. For this purpose, we selected all NF-κB target
genes, which were previously reported by Feuerhake et
al.14 (Online Supplementary Table S2) and were present on
the U133A-array used in this study (106 of the 116
probe sets reported, representing 68 genes). We subject-
ed these 106 probe sets to a global test for differential
gene expression24 between cases with and without a
18q21 gain. We found that this set of genes together
displayed global changes in gene expression
(p<0.0001), if the ABC/GCB status, which overlaps
with the presence of a 18q21 gain, was ignored.
However, the significance was lost when the
ABC/GCB status was taken into account as a con-
founding factor within the test (p=0.12). We cannot,
therefore, distinguish between 18q21/MALT1- related
and ABC-related effects on the expression of the ana-
lyzed NF-κB target genes.
Correlation with histopathology
In the group with a 18q21/MALT1 gain, the histo-
pathological panel review classified the DLBCL as fol-
lows: centroblastic variant (n=31; 71%), plasmablastic
variant (n=4; 9%), immunoblastic variant (n=2; 4%),
and anaplastic variant (n=1; 2%). In six cases (14%) a
definitive assignment to one of the WHO DLBCL vari-
ants was not possible. In the cases without a
18q21/MALT1 gain the following DLBCL variants were
observed: centroblastic variant (n=46; 64%), immuno-
blastic variant (n=7; 10%), plasmablastic (n=3; 4%),
anaplastic variant (n=2; 3%). In 14 DLBCL cases with-
out a 18q21/MALT1 gain (19%) a clear subgrouping
according to the WHO classification was not possible.
All cases with a 18q21/MALT1 gain showed BCL2
protein expression, whereas 79% of the other cases did
so (p<0.001) (Table 1). In addition, the Ki-67 index, a
marker of cell proliferation, was significantly higher in
the group with a 18q21/MALT1 gain (p=0.016) (Table
1). CD10 expression tended to be higher in the group
without a 18q21/MALT1 gain (p=0.056), which might
be related to the higher frequency of GCB-type
DLBCL. No significant difference was found in BCL6
protein expression (p=0.1) (Table 1).
Interestingly, among the cases with a 18q21/MALT1
gain, four showed concomitant amplification of
MALT1 and BCL2. These cases were diagnosed as
DLBCL centroblastic variant and did not differ mor-
phologically or immunophenotypically from the other
cases with a gain of 18q21/MALT1. One further case
showing a MALT1 amplification but normal BCL2 sta-
tus was detected and diagnosed as DLBCL centroblas-
tic variant without evidence that this case represented
a transformed marginal zone B-cell lymphoma. 
Correlation with clinical parameters and prognosis:
gain of 18q21 including MALT1 is an independent
negative prognostic factor in DLBCL
Concerning known clinical risk factors, the patients
in the group with a 18q21/MALT1 gain showed a trend
to more frequent bone marrow involvement (21% vs.
6%, p=0.097). There was no significant difference with
respect to age, sex ratio, B-symptoms, bulky disease,
extranodal involvement, lactate dehydrogenase level,
or applied therapy including the use of rituxan (Table
2). In univariate analysis, we found a lower fraction of
patients reaching a complete remission and a higher
number of patients with progressive disease (p=0.014)
in the group with a 18q21/MALT1 gain (Table 2). Time-
to-treatment-failure was not significantly shorter in the
group with a 18q21/MALT1 gain (p=0.12), but we
found a trend to a shorter overall survival (5-year sur-
vival, 28% vs. 38%, p=0.09),
In the multivariate analysis incorporating age, Ann
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Arbor stage, a break within the MYC gene, ABC/GCB
gene expression subtype, and 18q21/MALT1 status in
all patients for whom information on these factors was
available (n=71), the 18q21/MALT1 status remained an
independent negative prognostic factor for overall sur-
vival [hazard ratio 2.13 (95% CI: 1.08-4.23), p=0.03]. 
Discussion
The 116 DLBCL analyzed in our study were diag-
nosed according to the histopathological and immuno-
histochemical characteristics described in the WHO
classification and additionally according to novel gene
expression features recently defined by our group.10
Forty-three of our 116 cases of DLBCL had a genom-
ic gain of BCL2 and MALT1 and one case revealed an
amplification of MALT1 together with a normal BCL2
gene status (together 38%), while 72 cases (62%) had
normal copy numbers of the BCL2 and MALT1 genes
not considering changes in ploidy. Interestingly, gain of
the BCL2 gene was invariably associated with gain of
the MALT1 gene in our series. Moreover, the presence
of a 18q21/MALT1 gain correlated with upregulation of
genes located on 18q including MALT1 at the RNA
level, independently of the ABC or GCB gene expres-
sion signature, and was strongly associated with over-
expression of BCL2 protein. We found a significant
accumulation of cases with a 18q21/MALT1 gain
among those with an ABC signature and 98 differen-
tially expressed genes between the two genetic groups
of DLBCL, including some selected NF-κB target genes.
However, when we included the ABC/GCB signature
as a confounding factor into the test, the influence of
the 18q21/MALT1 gain on gene expression was no
longer significant. The overlap of ABC and 18q21 gains
complicated efforts to distinguish effects on gene
expression specific to ABC status or 18q21 gains. Linear
models generated in all steps of analysis allowed us to
test for differential gene expression (18q21 gain vs. nor-
mal) while taking into account the presence of an addi-
tional confounding factor (ABC vs. GCB signature). We
interpret this by the unequal distribution of the DLBCL
cases with and without 18q21/MALT1 gains in the
ABC- and GCB-categories. As a result, we could not
distinguish 18q21/MALT1- specific from ABC-specific
effects on gene expression.
BCL2 and MALT1 are both located on chromosome
18q21, about 5 Mb apart from each other, and are both
key genes in the pathogenesis of different subtypes of
non-Hodgkin’s lymphomas. MALT1 codes for a para-
caspase, a scaffold protein recently proposed to be
related to selective control of the c-Rel subunit in the
canonical NF-κB pathway.28 The API2-MALT1 fusion
protein resulting from the t(11;18)(q21;q21)29-31 and the
overexpressed MALT1 protein in another MALT1-asso-
ciated translocation in MALT lymphomas, the t(14;18)
(q32;q21),32,33 have been shown to activate NF-κB and
thereby promote cellular proliferation and resistance to
apoptosis.34-36 In addition to the two translocations,
amplifications and gains of MALT1 have been
described in different subtypes of non-Hodgkin’s lym-
phomas,32,37 but their pathophysiological significance is
not known.
BCL2 is a gene involved in the regulation of apopto-
sis and plays a major role in the response of malignant
cells to a variety of stresses that may lead to apoptosis,
including chemotherapy.38 One major mechanism lead-
ing to BCL2 protein overexpression is the t(14;18)
(q32;q21) resulting in juxtaposition of the BCL2 gene
and the IGH locus. The t(14;18) is found in most follic-
ular lymphomas and about 20% of DLBCL.11,39 The
t(14;18) occurs mainly in GCB-DLBCL, being present in
approximately 35% of these cases. In GCB-DLBCL, the
t(14;18) correlates with BCL2 mRNA and protein
expression,39 indicating that this is the major mecha-
nism in upregulation of BCL2 expression in this sub-
group. 
However, ABC-DLBCL also have high levels of BCL2
expression in the absence of t(14;18), indicating alterna-
tive mechanisms of BCL2 upregulation. Using inter-
phase FISH, Iqbal et al. recently showed that BCL2 pro-
tein expression in ABC-DLBCL is significantly associat-
ed with genomic gain of BCL2.16 In another study, gain
of 18q21-22 was detected by CGH in one third of ABC-
DLBCL, but less frequently in GCB-DLBCL (10%) and
PM-DLBCL (16%).40 Our study revealed compatible
results with an accumulation of cases with a gain or
amplification of the BCL2 and MALT1 genes in the
ABC subtype as well as a highly significant association
of these gains with BCL2 RNA and protein expression. 
We additionally showed that a gain of BCL2 was
accompanied by a gain of MALT1 in all of our cases of
DLBCL. In line with this observation, gain of BCL2 was
associated with gain of MALT1 in one study analyzing
lymphoma cell lines by array-CGH and in a further
study using array-CGH and quantitative PCR to evalu-
ate DLBCL patients with chromosomal gains in 18q21-
q22.32,40 Most other studies applied conventional CGH
analysis or interphase FISH with BCL2-specific probes.
It is not, therefore, possible to assess in these studies
whether or not MALT1 was gained in addition to
BCL2.16,41 Despite the scarcity of data, the frequent
association of genomic gains of BCL2 and MALT1
might suggest a cooperative action of these two and
possibly additional 18q21 genes in DLBCL.
Given that BCL2 is transcriptionally regulated by NF-
κB17 and NF-κB is activated by MALT1, which was
found to be upregulated on genomic and RNA levels in
our study, we evaluated the differential expression of
68 selected NF-κB target genes in our DLBCL cases.
There were significant changes in the expression of this
set of genes between the two MALT1 genetic groups;
however, the significance was lost when ABC/GCB
status was included as a confounding factor in the test.
Hence, also for the analyzed NF-κB target genes, it was
not possible to distinguish between 18q21/MALT1- and
ABC-related effects on their expression. 
In contrast to the analyzed NF-κB target genes and
the global differential gene expression between the two
genetic groups, the differential expression of MALT1
itself and 32 other genes located on chromosome 18q
was independent of the gene expression subtype. We
focused our investigations on the MALT1 gene, but can-
J. Dierlamm et al. 
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not exclude that any of the other 32 genes may play a
pathogenetic role in DLBCL cases with a 18q21 gain.
The pathogenetic mechanism of action of MALT1 and
the other 18q genes in this context cannot be conclud-
ed from our data. 
We found that gain of 18q21 including MALT1 and
BCL2 was an independent negative prognostic factor in
our cases of DLBCL, although the relatively small num-
ber of patients and the heterogeneous treatment proto-
cols applied should be taken into account when inter-
preting this result. In the multivariate analysis including
age, Ann Arbor stage, a break within the MYC gene,
ABC/GCB gene expression subtype, and 18q21/MALT1
status, 18q21/MALT1 status was a statistically signifi-
cant independent negative prognostic factor for overall
survival (hazard ratio 2.13, p=0.03). In the univariate
analysis, response to treatment was significantly
reduced (p=0.014) and a trend to a shorter overall sur-
vival (p=0.09) was demonstrated. 
Bea et al. found overrepresentation of 18q in DLBCL
to be significantly associated with a primary nodal
presentation, high serum lactate dehydrogenase, and
high International Prognostic Index score.41 In addition,
18q gains were more commonly found in tumors with
a higher number of chromosomal imbalances.41 Similar
to the present study, patients with 18q gain had a sig-
nificantly shorter cause-specific overall survival, higher
risk of relapse, and a tendency to lack a complete
response to treatment.41 This relationship between 18q
gains and a more aggressive clinical behavior in DLBCL
had not been well recognized previously. A recent
study on follicular lymphoma identified a distinct clin-
ical presentation in patients with 18q gains, although
no differences were observed in outcome.42 In another
study, dup(18q) was found to predict an unfavorable
overall survival in follicular lymphomas with the
t(14;18).43 In surgically resected t(11;18)-negative gas-
trointestinal DLBCL, trisomy of 18q21, as shown by
interphase FISH, was also associated with a shorter
overall survival.44
The various reports in the literature on the t(14;18) or
BCL2 expression as a prognostic indicator in DLBCL
have been inconclusive.45-49 Interestingly, a recent study
showed that BCL2 protein expression represents a neg-
ative prognostic factor in the ABC-DLBCL subgroup,
but not in the GCB subgroup.16 In the latter study, BCL2
protein expression in the ABC-DLBCL subgroup was
associated with amplification and gain of the BCL2
gene,16 which was also demonstrated in the present
study. Since 18q21/MALT1-positive cases are frequent-
ly found in the ABC-DLBCL subgroup, it cannot be
excluded that this prognostically unfavorable gene
expression subtype had an influence on the clinical
course in our study. 
In summary, our data demonstrate that a gain of
18q21 including MALT1 is associated with differential
RNA expression of genes located on 18q, independent-
ly of the gene expression subtype, as well as BCL2 pro-
tein expression and clustering in the ABC subtype. The
differences in expression of genes not located on 18q,
including the analyzed NF-κB target genes, overlapped
with the ABC/GCB, gene expression subtype. So, the
individual influence of the gene expression signature
and the 18q21/MALT1 status on gene expression can-
not be viewed separately. Finally, 18q21/MALT1 gain
may be a prognostic indicator in DLBCL, although this
needs further evaluation in a prospective trial with
homogeneously treated patients combining genomic
analysis and gene expression profiling.
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